Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Ipamorelin vs Lonapegsomatropin (Skytrofa)
An educational, source-based comparison of Ipamorelin and Lonapegsomatropin (Skytrofa) — how each peptide works, what it's researched for, and what to know before going deeper.
A selective ghrelin/GHS-R1a receptor agonist that stimulates GH release with minimal effect on cortisol, prolactin, or appetite — distinguishing it from older secretagogues like GHRP-6.
- Endogenous GH release without cortisol elevation
- Sleep quality and recovery markers
- Lean tissue retention in catabolic states
- • Generally well tolerated in research; long-term human safety data are limited.
- • Not FDA-approved.
- • Use in sport is prohibited (WADA).
Prodrug of somatropin with a transient PEG linker that releases unmodified GH over ~1 week, providing once-weekly dosing for pediatric GH deficiency.
- Pediatric growth hormone deficiency
- • FDA-approved.
- • Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Ipamorelin | Ipamorelin, the first selective growth hormone secretagogue | European Journal of Endocrinology | 1998 | Characterized selectivity for GH release without affecting ACTH, cortisol, or prolactin. |
| Lonapegsomatropin (Skytrofa) | heiGHt trial | JCEM | 2021 | Non-inferior annualized height velocity vs daily somatropin. |
Side-effect & safety grid
- Generally well tolerated in research; long-term human safety data are limited.
- Not FDA-approved.
- Use in sport is prohibited (WADA).
- FDA-approved.
- Same class warnings as daily GH (intracranial hypertension, scoliosis progression, glucose intolerance).
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Ipamorelin vs Lonapegsomatropin (Skytrofa) — Key differences
- Class: Ipamorelin is classified as Growth Hormone Axis, while Lonapegsomatropin (Skytrofa) is GH Analog · Endocrine.
- Primary research focus: Ipamorelin — endogenous gh release without cortisol elevation; Lonapegsomatropin (Skytrofa) — pediatric growth hormone deficiency.
- Tag: Recovery · Sleep vs FDA-Approved · Endocrine.